30413-61-7

Upstream product

• 3510-66-5 2-Bromo-5-methylpyridine 
• 1066-54-2 trimethylsilylacetylene 
• 872428-46-1 5-methyl-2-((trimethylsilyl)ethynyl)pyridine 
• 22282-62-8 2-iodo-5-methyl-pyridine 

Downstream Products

• 884494-43-3 2-(2-methoxyphenyl)-5-methyl-pyridine 
• 540508-54-1 4-(5-methylpyridin-2-yl)phenol 
• 1292785-58-0 3-ethoxy-4-(5-methylpyrid-2-yl)phenol 
• 1429635-38-0 4-(5-(3,4-dimethoxybenzyl)-1H-1,2,4-triazol-1-yl)-2-methyl-6-((5-methylpyridin-2-yl)ethynyl)pyrimidine 
• 1448017-12-6 5-methyl-2-[2-(5-methylpyridin-2-yl)-6-vinylphenyl]pyridine 
• 7048-39-7 2-(2-benzo[b]furanyl)-5-methylpyridine 
• 1429635-39-1 4-(5-(3,4-dimethoxybenzyl)-1H-1,2,4-triazol-1-yl)-2-methyl-6-((5-methylpyridin-2-yl)ethyl)pyrimidine 

Relevant academic research and scientific papers

INHIBITORS FOR THE Β-CATENIN / T-CELL FACTOR PROTEIN–PROTEIN INTERACTION

Disclosed are inhibitors for the β-catenin/T-cell factor interaction. The inhibitors are selective for β-catenin/T-cell factor over β-catenin/cadherin and β-catenin/APC interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.

MGLUR REGULATORS

Provided herein are compounds of the formula I: (I), as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment or prevention of mGluR5 mediated disorders, such as acute and/or chronic neurological disorders, cognitive disorders and memory deficits, as well as acute and chronic pain.

Efficient synthesis of 2-pyridylenynes and application in cobalt-catalysed benzannulation reactions

The cobalt-catalysed benzannulation of 2-pyridine-substituted enynes gave 2,3-bis(2-pyridyl)styrenes in moderate yields. The reaction with dibromomethane as well as diiodomethane generated the corresponding planar-chiral bispyridinium salts in good yields

PYRIMIDINE PDE10 INHIBITORS

The present invention is directed to pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Synthesis of functionalized arylpyridines and -pyrimidines by domino [4+2]/retro [4+2] cycloadditions of electron-rich dienes with alkynylpyridines and -pyrimidines

Aryl-substituted pyridines and pyrimidines were prepared by [4+2] cycloadditions of alkynyl-substituted pyridines and -pyrimidines with electron-rich dienes. The reactions proceed by formation of a bridged cycloadduct and subsequent thermal extrusion of ethylene. The pyridine moiety plays a crucial role for the success of the reaction.

Reductive Amination of Ethynylpyridines with Sodium Cyanoborohydride

In order to investigate the structure-activity relationship of betahistine derivatives, a general synthesis of methylated 2-(2-methylaminoethyl)pyridines was developed based on the addition of methylamine hydrochloride to methylated 2-ethynylpyridines under reductive conditions.In addition, the scope and limitations of the reductive addition were briefly examined.For example, the reaction proceeded smoothly with p-nitrophenylacetylene, whereas phenylacetylene itself did not react with methylamine.Keywords - ethynylpyridine; sodium cyanoborohydride; reductive amination; betahistine; palladium-catalyzed reaction; ethyl pyridineacetate; 2-(2-pyridyl)ethylamine